Core Viewpoint - Innovent Biologics has received acceptance for the New Drug Application (NDA) of picankibart injection, an IL-23p19 antibody, for treating moderate to severe plaque psoriasis in China, marking a significant milestone for the company and the treatment landscape in the region [1][2][3]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing high-quality medicines for various diseases, including oncology, autoimmune, cardiovascular, and metabolic conditions [7]. - The company has launched 11 products and has multiple assets in various stages of clinical trials, including 3 new drug applications under regulatory review [7]. Product Details - Picankibart (IBI112) is a monoclonal antibody that targets the IL-23p19 subunit, showing over 80% of subjects achieving PASI 90 after 16 weeks in a Phase 3 clinical trial [1][6]. - The drug offers the longest maintenance dosing interval in its class, administered once every 12 weeks, which enhances patient convenience and quality of life [1][2]. Clinical Study Insights - The NDA acceptance is based on positive results from the CLEAR-1 Phase 3 clinical study, which met all primary and key secondary endpoints, demonstrating significant skin lesion clearance and quality of life improvement compared to placebo [2][3]. - The safety profile of picankibart was favorable, with no new safety signals reported during the trial [2]. Market Context - Psoriasis is a chronic, recurrent inflammatory disease affecting a significant portion of the population, with approximately 80% to 90% of patients having plaque psoriasis, and nearly 30% of these cases classified as moderate to severe [4]. - The global prevalence of psoriasis is notable, with over 7 million patients in China alone, highlighting the potential market for effective treatments like picankibart [4]. Future Directions - Innovent plans to continue its communication with regulatory authorities during the NDA review process and aims to validate more clinical value of picankibart through additional studies [3][6]. - The company is also expanding its innovative portfolio in other therapeutic areas, including ophthalmology and cardiovascular diseases, to address unmet medical needs [3][7].

Core Insights - Innovent Biologics presented clinical data for IBI363, a first-in-class PD1/IL-2α-bias bispecific antibody fusion protein, combined with bevacizumab for advanced colorectal cancer at the 2024 ESMO Congress [1][6] - The combination therapy demonstrated promising anti-tumor efficacy and a manageable safety profile in patients with advanced colorectal cancer [2][3] Group 1: Clinical Study Results - A total of 35 subjects were treated with IBI363 and bevacizumab, showing a 21.9% overall response rate (ORR) and a 65.6% disease control rate (DCR) [2][3] - The median duration of response (DoR) was 8.1 months, with a median progression-free survival (PFS) of 4.1 months [3] - Among subjects with liver metastases, the ORR was 11.8%, while those without had an ORR of 33.3% [3] Group 2: Efficacy in Different Patient Populations - In patients who had received prior immunotherapy, the ORR was 25.0%, compared to 20.8% in immunotherapy-naïve patients [4] - For patients with KRAS/NRAS exon 2/3/4 mutations, the ORR was 21.4%, while those without such mutations had an ORR of 30.0% [4] Group 3: Safety Profile - The most common treatment-related adverse events included arthralgia, thyroid disorders, and rash, with a total incidence of grade 3 or higher adverse events at 22.9% [2] - Immune-related adverse events of grade 3 or higher occurred in 5.7% of subjects, indicating a safety profile similar to IBI363 monotherapy [2][6] Group 4: Future Development and Potential - Ongoing studies are exploring IBI363 in other malignancies and combination regimens for advanced colorectal cancer, with updates expected at future academic conferences [5] - The combination of IBI363 and bevacizumab is seen as having significant potential for treating non-MSI-H/dMMR advanced colorectal cancer, a population with limited response to current immunotherapies [6][7]

Core Viewpoint - Innovent Biologics has announced positive Phase 3 clinical trial results for mazdutide, a dual agonist for GLP-1R and GCGR, showing superior efficacy in glycemic control and weight loss compared to dulaglutide in Chinese adults with type 2 diabetes [1][2][3]. Group 1: Clinical Trial Results - The DREAMS-2 trial involved 731 Chinese participants with type 2 diabetes, demonstrating that mazdutide 4 mg and 6 mg achieved mean reductions in HbA1c of 1.69% and 1.73%, respectively, compared to 1.36% for dulaglutide [2][3]. - At week 28, 71.2% and 74.2% of participants on mazdutide achieved HbA1c <7.0%, while 62.1% achieved this with dulaglutide [3]. - Participants on mazdutide experienced significant weight reductions of 9.24% and 7.13% for the 4 mg and 6 mg doses, respectively, compared to 2.86% for dulaglutide [4]. Group 2: Cardiometabolic Benefits - Mazdutide treatment led to improvements in multiple cardiometabolic risk factors, including fasting glucose, blood pressure, lipids, and liver enzymes, with results generally superior to dulaglutide [5]. - The treatment also showed a favorable safety profile, with low rates of treatment-emergent adverse events (TEAEs) leading to discontinuation and no new safety signals reported [6]. Group 3: Regulatory Status and Market Potential - Mazdutide is currently under review for two New Drug Applications (NDAs) in China: one for chronic weight management and another for glycemic control in type 2 diabetes [10]. - The company has multiple ongoing Phase 3 studies for mazdutide, indicating a strong pipeline and potential for significant market impact in diabetes treatment [10][11]. Group 4: Industry Context - The prevalence of diabetes in China is projected to reach 174 million by 2045, highlighting the urgent need for effective treatments [8]. - GLP-1 receptor agonists, including mazdutide, are becoming increasingly important in the management of type 2 diabetes, offering comprehensive benefits beyond glucose control [7].

Core Insights - Innovent Biologics announced Phase 1 clinical data for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at the 2024 World Conference on Lung Cancer, focusing on its application in advanced non-small cell lung cancer (NSCLC) [1][4] Group 1: Clinical Data and Efficacy - As of August 2, 2024, 134 patients were enrolled in the study, with 95.5% having received prior PD-(L)1 immunotherapy. The overall objective response rate (ORR) was 20.8% and disease control rate (DCR) was 74.4% [1][3] - In the subgroup receiving 3 mg/kg Q3W, the ORR was 34.5% and DCR was 79.3%, with a notable 50% ORR and 88.9% DCR among patients with at least 12 weeks of follow-up [2][3] - The median progression-free survival (PFS) for patients treated with 1/1.5 mg/kg was 5.5 months, while the median PFS for the 3 mg/kg group has not yet been reached [3] Group 2: Safety Profile - IBI363 demonstrated a manageable safety profile, with 20.1% of patients experiencing treatment-related adverse events (TRAEs) of grade 3 or higher, and 6.0% discontinuing treatment due to TRAEs [3] - In the 3 mg/kg Q3W subgroup, 17.5% experienced TRAEs ≥ grade 3, and 5.3% discontinued treatment due to TRAEs, indicating consistency in safety across different dosage groups [3] Group 3: Future Directions - The company plans to continue investigating the long-term efficacy and safety of IBI363, as well as its potential in combination with other therapies and in different solid tumors [4] - Additional studies are underway to evaluate IBI363's effectiveness in treating cold tumors with low or absent PD-L1 expression, which could represent a significant advancement in NSCLC treatment [5][6] Group 4: Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, including cancer and autoimmune disorders. The company has launched 11 products and has multiple assets in clinical trials [7][8]

Investment Rating - The report gives a "Buy" rating for the company with a target price of HKD 58.05 [5] Core Views - The company has a strong R&D engine and commercialization capabilities, aiming for RMB 20 billion in revenue by 2027 [1] - The company has 11 approved products, with product revenue reaching RMB 3.8 billion in H1 2024, a 55% YoY increase [1] - The company is focusing on four key disease areas: oncology, cardiovascular & metabolic, autoimmune, and ophthalmology, with a diversified product pipeline [1] - The company expects to have nearly 20 approved products by 2027, targeting RMB 20 billion in domestic revenue [1] Oncology - The company has 9 approved oncology products, with 1 NDA submitted and 2 in key clinical stages [2] - Sintilimab (PD-1) sales reached RMB 2.75 billion in 2023, a 34% YoY increase, and is expected to maintain growth due to its inclusion in the national reimbursement drug list (NRDL) [2] - The company is developing next-generation IO therapies, including a global first-in-class PD-1/IL-2 bispecific antibody (IBI363), which has shown promising efficacy in Phase I trials [2] - The company is leveraging its "IO+ADC" dual strengths, with IBI343 (CLDN18.2 ADC) showing potential as a best-in-class ADC in gastric and pancreatic cancers [34] Metabolic and Cardiovascular - Mazdutide (GLP-1R/GCGR dual agonist) is the first GLP-1R/GCGR dual agonist to enter Phase III globally, with NDAs submitted for obesity and type 2 diabetes [3] - Mazdutide has shown significant weight loss and glycemic control in clinical trials, with potential to become a leading treatment for obesity and diabetes [44] - Tafolecimab (PCSK9 inhibitor) is the first domestically developed PCSK9 monoclonal antibody approved in China, with potential for inclusion in the NRDL in 2024 [49] Autoimmune and Ophthalmology - The company has a strong pipeline in autoimmune diseases, including IBI112 (IL-23p19 inhibitor) for psoriasis, which has shown best-in-class potential with a 12-week dosing interval [3] - IBI311 (IGF-1R inhibitor) is expected to be the first innovative drug for thyroid eye disease (TED) in China, with NDA submitted [3] Financial Projections - The company is expected to achieve revenues of RMB 8 billion, RMB 11 billion, and RMB 14.7 billion in 2024, 2025, and 2026, respectively, with YoY growth rates of 29%, 37%, and 34% [3] - Net profit is projected to turn positive in 2025, reaching RMB 121 million, and further increase to RMB 1.34 billion in 2026 [3] - The company's DCF valuation suggests a fair value of HKD 58.05 per share, with a market cap of HKD 94.7 billion [3]

Core Insights - Innovent Biologics has announced updated results from a pivotal Phase 2 clinical trial of Dupert® (fulzerasib) for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation, presented at the 2024 World Conference on Lung Cancer [1] - Fulzerasib has received approval from the NMPA in August 2024 for treating adult patients with advanced NSCLC harboring the KRAS G12C mutation who have received at least one systemic therapy [1][2] - The clinical trial showed a confirmed objective response rate (ORR) of 49.1% and a disease control rate (DCR) of 90.5%, with a median progression-free survival (PFS) of 9.7 months [1] Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing high-quality medicines for various diseases, including cancer and autoimmune disorders [3] - The company has launched 11 products and has multiple assets in various stages of clinical trials, including 3 new drug applications under regulatory review [3] - Innovent collaborates with over 30 global healthcare companies, enhancing its research and development capabilities [3] Product Details - Fulzerasib is a novel, orally active KRAS G12C inhibitor designed to target the GTP/GDP exchange, leading to tumor cell apoptosis and cell cycle arrest [2] - The KRAS G12C mutation is prevalent in various cancers, including 15-20% of lung cancers, making it a significant target for treatment [2] - The drug has received Breakthrough Therapy Designation from the CDE of China's NMPA for treating advanced NSCLC and colorectal cancer patients with KRAS G12C mutation [2]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$61.98, reflecting a potential upside of 42% from the current price of HK$43.50 [2][4][8]. Core Insights - The company is expected to achieve a revenue CAGR of approximately 30% from 2024 to 2026, driven by strong market demand for its products [2][3]. - The company reported a significant increase in product revenue for 1H24, reaching RMB 3.81 billion, a year-on-year growth of 55.1% [2][6]. - The gross margin for 1H24 was 84.1%, an increase of 1.8 percentage points compared to the previous year, attributed to rising sales and decreasing production costs [2][3]. - The company has multiple key products in the cardiovascular and metabolic (CVM) fields awaiting approval, which are considered crucial for future growth [2][3]. Financial Summary - The company's revenue is projected to grow from RMB 6,206 million in 2023 to RMB 12,948 million by 2026, with a gross profit increasing from RMB 5,070 million to RMB 10,667 million over the same period [1][12]. - The net profit is expected to turn positive by 2025, reaching RMB 1,004 million, and further increasing to RMB 2,508 million by 2026 [1][12]. - The earnings per share (EPS) is forecasted to improve from a loss of RMB 0.66 in 2023 to a profit of RMB 1.61 by 2026 [1][12]. Valuation Analysis - The report employs a two-stage DCF valuation method, resulting in a target price of HK$61.98, which corresponds to a 2025 enterprise value/revenue multiple of 7.7x, significantly higher than the comparable company average of 4.0x [8][9]. - The WACC used in the valuation is 10.2%, with a perpetual growth rate of 3% [8][9].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights strong growth in product sales and a significant narrowing of adjusted LBITDA. The total revenue for the first half of 2024 reached 39.52 billion CNY, representing a year-on-year increase of 46.3%, with product revenue at approximately 38.11 billion CNY, up 55.1% year-on-year. The company reported a loss of 3.93 billion CNY, compared to a loss of 1.39 billion CNY in the same period of 2023. Adjusted LBITDA was 1.61 billion CNY, down from 2.67 billion CNY in 2023, marking a 39.9% reduction in losses [3] Summary by Sections Financial Performance - In the first half of 2024, adjusted R&D expenses were 12.94 billion CNY, compared to 8.26 billion CNY in the same period of 2023. Adjusted selling expenses were 18.51 billion CNY, accounting for 46.8% of revenue, a decrease of 2.8 percentage points year-on-year. The adjusted gross margin was 84.1%, up from 82.3% in the same period of 2023, due to increased sales volume and improved production efficiency [3][4] Product Development - The company announced that its KRAS G12C inhibitor, Daberit®, received NMPA approval for use in adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations. This is the first KRAS G12C inhibitor approved in China and marks the company's 11th product [3] Future Growth Prospects - The company has a robust pipeline with 11 approved products and 3 new products in the NDA stage. Six additional product applications are currently under review. The company aims to commercialize 20 products by 2027, targeting sales revenue of 20 billion CNY [3][4] Profit Forecast - The company is projected to have a net profit of -6.05 billion CNY in 2024, followed by 3.04 billion CNY in 2025 and 10.22 billion CNY in 2026, with year-on-year growth rates of 41%, 150%, and 236% respectively. The long-term development outlook is positive, leading to the maintenance of the "Buy" rating [3][4]

Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics with a target price adjusted to HKD 67.8 per share [9][17]. Core Insights - Innovent Biologics reported strong revenue growth in H1 2024, with total revenue reaching RMB 39.5 billion, a 46.3% increase year-on-year, and product revenue of RMB 38.1 billion, up 55.1% [3][14]. - The company's gross margin improved to 82.9%, reflecting operational efficiency enhancements, while R&D expenses increased by 51.6% to RMB 14.0 billion, accounting for 35.4% of revenue [3][14]. - The report highlights the successful sales performance of key products, including Tyvyt (PD-1 inhibitor) and several biosimilars, contributing to the revenue growth [4][14]. Financial Performance - For H1 2024, the company reported a net loss of RMB 3.9 billion, compared to a loss of RMB 1.4 billion in the same period last year [3][14]. - Adjusted LBITDA for the period was RMB 1.6 billion, a decrease of 39.9% from RMB 2.7 billion in the previous year [3][14]. - As of June 30, 2024, the company had cash and short-term financial assets totaling RMB 101.1 billion [3][14]. Product Pipeline and Growth Potential - The oncology pipeline is rich with catalysts, including the recent NMPA approval of Fulzerasib (KRAS G12C) and expected approval of IBI344 (ROS1) in H2 2024 [5][15]. - Upcoming clinical data updates for several early-stage products are anticipated, including IBI363 (PD-1/IL-2 α-bias) and IBI343 (CLDN18.2 ADC) [5][15]. - The non-oncology field is also progressing, with NDA submissions for Mazdutide (GLP-1R/GCGR) and Teprotumumab (IGF-1R) expected to bolster future revenue [5][16]. Revenue Forecast - Revenue forecasts for 2024-2026 have been adjusted to RMB 78.6 billion, RMB 102.5 billion, and RMB 133.9 billion, respectively, reflecting year-on-year growth rates of 26.7%, 30.3%, and 30.7% [9][17]. - The company is projected to achieve profitability by 2026, with a net profit attributable to shareholders of RMB 760 million [9][17].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price raised to HKD 55.40 [3][4]. Core Insights - The company reported a strong sales performance in the first half of 2024, with a year-on-year revenue increase of 46.3% to RMB 3.95 billion, driven by a 55.1% increase in pharmaceutical sales [2][3]. - Despite a significant increase in net loss by 182.1% to RMB 390 million, this was attributed to the absence of a one-time tax refund from the previous year and an increase in R&D expenses [2]. - Revenue forecasts for 2024-2026 have been adjusted upwards, with a projected CAGR of 26.4% from 2023 to 2026 [3]. Summary by Sections Revenue and Profit Forecasts - The revenue forecast for 2024 has been slightly increased by 0.04%, with 2025 and 2026 revenue estimates raised by 4.4% and 5.9% respectively [3][6]. - The company expects a revenue CAGR of 26.4% from 2023 to 2026, driven by growth in existing and new products [3]. Product Pipeline - The core product, Dabu, continues to see increased indications, with a revenue increase of 45.6% in the first half of 2024, amounting to USD 239 million (approximately RMB 1.68 billion) [3]. - New products launched post-2020 have significantly contributed to revenue, with their share rising from 26.6% in 2021 to 58.8% in the first half of 2024 [3]. - The recently launched Dabot will contribute to revenue in the second half of the year, targeting a significant market in non-small cell lung cancer [3]. Financial Metrics - The company’s total revenue is projected to reach RMB 8.318 billion in 2024, RMB 10.437 billion in 2025, and RMB 12.538 billion in 2026, with respective growth rates of 34.0%, 25.5%, and 20.1% [7]. - The net loss is expected to decrease from RMB 729 million in 2024 to RMB 400 million in 2026, indicating a path towards profitability [7]. Valuation - The updated DCF model reflects an increase in the target price from HKD 51.05 to HKD 55.40, based on the upward revision of net profit forecasts for 2025-2026 [3][4].